Results 201 to 210 of about 247,670 (219)
Some of the next articles are maybe not open access.
Diffuse Large B-Cell Lymphomas and Burkitt Lymphoma
Hematology/Oncology Clinics of North America, 2009Diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphoma (BL) account for the majority of aggressive lymphomas in adults and children. DLBCLs exhibit marked biological heterogeneity and variable clinical presentation and clinical course. Conversely, BL is genetically relatively homogeneous but associated with variable clinicopathological features ...
Laurence, de Leval +1 more
openaire +2 more sources
Pancreatic Diffuse Large B-Cell Lymphoma
Journal of Gastrointestinal Surgery, 2023Cuiping Zhang, Keping Tan, Jun Li
openaire +2 more sources
Diffuse Large B-Cell Lymphomas
2010De novo diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide, accounting for approximately 30–40% of adult non-Hodgkin lymphomas. It is defined as a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding that of a normal macrophage or more than twice the size of a normal lymphocyte ...
openaire +2 more sources
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Nature, 2000Ash A. Alizadeh +30 more
semanticscholar +1 more source
Endobronchial Diffuse Large B-cell Lymphoma
Archivos de Bronconeumología (English Edition), 2020Masahiro, Yamasaki +2 more
openaire +2 more sources
2001
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach.
John W. Sweetenham +3 more
openaire +1 more source
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach.
John W. Sweetenham +3 more
openaire +1 more source
Treatment resistance in diffuse large B-cell lymphoma
Leukemia, 2021Michael Y. He, R. Kridel
semanticscholar +1 more source

